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PGE2-JNK signaling axis non-canonically promotes Gli
activation by protecting Gli2 from ubiquitin-proteasomal
degradation
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Both bench and bedside investigations have challenged the supportive role of Hedgehog (Hh) activity in the progression of
colorectal cancers, thus raising a critical need to further deeply determine the contribution of Hh to the growth of colorectal cancer.
Combining multiple complementary means, including in vitro and in vivo inflammatory colorectal cancer models, and pathological
analysis of clinical colorectal cancer patients samples. We report that colorectal cancer cells hijack prostaglandin E2 (PGE2) to non-
canonically promote Hh transcriptional factor Gli activity and Gli-dependent proliferation of colorectal cancer cells in a Smo-
independent manner. Mechanistically, PGE2 activates c-Jun N-terminal kinase (JNK), which in turn enables Gli2 to evade ubiquitin-
proteasomal degradation by phosphorylating Gli2 at Thr1546. This study not only presents evidence for understanding the
contribution of Hh to colorectal cancers, but also provides a novel molecular portrait underlying how PGE2-activated JNK fine-tunes
the evasion of Gli2 from ubiquitin-proteasomal degradation. Therefore, it proposes a rationale for the future evaluation of
chemopreventive and selective therapeutic strategies for colorectal cancers by targeting PGE2-JNK-Gli signaling route.
Cell Death and Disease          (2021) 12:707 ; https://doi.org/10.1038/s41419-021-03995-z
INTRODUCTION
The Hedgehog (Hh) signaling pathway, which is evolutionarily
conserved across organisms ranging from insects to mammals,
plays a critical role in embryonic development and tissue
regeneration [1]. Binding ligands, including sonic Hh (SHh), Indian
Hh (IHh), and desert Hh (DHh), to the twelve transmembrane
receptor Ptch relieves the inhibitory effect on Smoothened,
another critical receptor of Hh pathway with G protein coupled
receptor-like structure. This subsequently causes accumulation of
Smo in the primary cilium and ultimately initiates the transcrip-
tional output of zinic finger transcriptional factor Gli, which
includes Gli1, Gli2, and Gli3. Among them, Gli2 functions as the
primary activator of Hh activity [2, 3]. Postnatal hyperactive Hh
signaling activity has been well characterized as a driver
contributor to the initiation and progression of various types of
cancers, including basal cellular carcinoma, medulloblastoma, and
rhabdomyosarcoma. Such cancers harbor aberrant Hh activity
commonly caused by genetic alterations in critical components of
the pathway, for example, Ptch, Smoothened, Sufu, etc [4–6]. The
approval of Hh inhibitors targeting Smo for clinical treatment of
advanced basal cell carcinoma further confirms the addiction of
this type of cancer to aberrant Hh pathway activity [7].
However, the contribution of Hh pathway activity to their
progression remains far from being fully elucidated, such as
colorectal cancers which rarely carry genetic changes in Hh genes
[5]. It has been initially suggested that Hh pathway activation in an
autocrine manner by the upregulated the expression of Hh ligands
in colorectal cancer cells promotes the growth and metastasis of
colorectal cancers [8, 9]. Many studies have also revealed that
stromal Hh pathway activity provoked by Hh ligands secreted by
colorectal cancer cells is essential for the carcinogenesis and
growth of colorectal cancer, which is reminiscent of the paracrine
activation of Hh pathway in mesenchymal cells during intestinal
development [10–14]. Unfortunately, these arguments are chal-
lenged by the discouraging results from a clinical trial with
vismodegib included in first-line therapy of metastatic colorectal
cancer [15]. Additional investigations reveal that stromal Hh
activity is required for the initiation of intestinal adenoma but not
for the subsequent tumor growth, and that the stromal Hh activity
is downregulated in colorectal cancer, while its restoration limits
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cancer growth [16]. Colorectal cancer is a leading cause of cancer
related mortality. A large body of evidence strongly indicates that
chronic inflammatory stimuli may increase risk of colorectal cancer.
Epidemiologic and clinic studies have revealed that non-steroidal
anti-inflammatory drugs (NSAIDs) may reduce the risk of colorectal
cancer, acting primarily through inhibiting cyclooxygenase-1 (COX-
1) and COX-2, two enzymes involved in prostaglandin biosynthesis.
COX2 expression has been found to be elevated in colorectal
cancers and to be associated with worse survival rate of colorectal
cancer patients [17, 18]. Prostaglandin E2 (PGE2) is the most
abundant prostaglandins found in colorectal cancers and the
major protumorigenic metabolites of inflammatory factor COX2
[18]. Despite multiple molecular mechanisms underpinning how
PGE2 promotes the initiation and progression of colorectal cancers
have been uncovered [19], the development of selective therapies
by targeting PGE2 signaling axis for colorectal cancers, a strategy
supposed to be better than targeting COX2 [20, 21], makes no
significant progress so far. This highlights a critical need to deeper
understand the molecular mechanisms behind how PGE2 pro-
motes the initation and progression of colorectal cancer, and to
identify novel druggable vulnerability downstream of PGE2 for
chemoprevention and selective therapies of colorectal cancers. In
this study, we investigated whether transcription factor Gli of Hh
pathway may be non-canonically activated by PGE2, thereby
promoting the initiation and progression of colorectal cancers.
MATERIALS AND METHODS
Cell culture and transfection
All the cell lines used in this study were purchased from the American Type
Culture Collection (Manassas, VA), and were routinely cultured in DMEM
supplemented with 10% fetal bovine serum (FBS) (Corning Life Sciences)
and 1% penicillin/streptomycin/L-glutamine (Corning Life Sciences). Cells
were periodically tested to be free of mycoplasma contamination. No cell
lines used in this study were found in the database of commonly
misidentified cell lines that is maintained by ICLAC and NCBI Biosample.
The plasmids and siRNAs were transfected using Lipofectamine 2000
according to the manufacturer’s instruction.
Animal studies
All animal studies conformed to our animal protocols approved by the
Animal Experimentation Ethics Committee of School of Pharmacy, Fudan
University. APCmin/+ mice were purchased from Jackson Laboratory (Bar
Harbor, ME). Male Apcmin/+ mice at age of 5 weeks old were treated with
vehicle, or PGE2 at 150 μg/100 μl/mouse by gavage twice per day in
combination with or without SP600125 at 50mg/kg by gavage once
per day, GDC-0449 at 25mg/kg by gavage twice per day, JQ1 at 100mg/kg
by gavage once per day for 6 weeks. Each mouse was randomly assigned to
each group and the investigator was blinded to the group allocation. After
the mice were sacrificed, the polyp number and size were counted and
measured under a Nikon SMZ1000 dissecting scope, and were harvested
for analyzing the expression of Hh target genes by real time PCR [22].
Human colorectal cancer tissue microarray
Human colorectal cancer tissue microarrays were obtained from Shanghai
Outdo Biotech CO., LTD. (HCol-Ade180Sur-06, Shanghai, China) containing
86 samples of different stages of colorectal cancers.
Plasmid constructions and siRNAs
The 8 × Gli-binding site luciferase reporter plasmid (GliBS) and mutant 8 ×
Gli-binding site luciferase reporter (mGliBS) were kindly provided by Dr.
Sasaki. The following plasmids were obtained from Addgene: pCDNA3 Flag
MKK7B2Jnk1a1(APF) (#19730, Addgene), pCDNA3 Flag MKK7B2Jnk1a1
(#19726, Addgene), pCDNA3 Flag Jnk1a1(apf) (#13846, Addgene), pCDNA3
Jnk1a1 (#13798, Addgene), pRK5-HA-Ubiquitin-WT (#17608, Addgene),
pBShh (#13996, Addgene). To generate the expression constructs for Gli2,
the PCS2-MT GLI2 FL vector obtained from Addgene (#17648, Addgene)
was subcloned into either pcDNA3.1 Myc or pcDNA3.1 HA vector. The Myc
tagged Gli2-expressing plasmid was further used to generate its mutants
Gli2 T1546A, and Gli2 T1546E using the Quick Change multi site-directed
mutagenesis kit from Stratagene (La Jolla, CA). The fragment 1 of Gli2 (Gli2-
F1) including 160–600 amino acids, the Gli2-F2 including 500–1100 amino
acids, and the fragment Gli2-F3 including 1000–1587 amino acids were
acquired through PCR and inserted in pGEX-6P-1 (GE Healthcare) for
constructing His fusion protein. The site mutant of Gli2-F3 T1546A was
generated from pGEX-6P-1 Gli2-F3 by using the Quick Change multisite-
directed mutagenesis kit from Stratagene.
The pre-designed siRNAs targeting Gli2 and Smo were obtained from
GenePharma (Shanghai, China).
Dual-luciferase reporter assay
Cells were seeded in 24-well plate and transfected with GliBS or mGliBS,
together with CMV/Renilla vector serving as an internal standard. After
overnight, the cells were subjected to various treatments as indicated,
followed by luciferase assay using a dual luciferase reporter assay system
(#E1960, Promega) according to the manufacturer’s instruction.
Real-time PCR analysis
Total RNA was extracted from cells using an RNAiso Plus Kit (TaKaRa;
Dalian, China) according to the manufacturer’s instructions, and directly
processed to cDNA by reverse transcription with a SuperScript III Kit
(#RR036A, TaKaRa). Semiquantitative PCR amplification was conducted
using Stratagene mx3005p (Agilent). The quantitative PCR amplifications
were performed in triplicate with a SYBR Green Kit (#RR086A, TaKaRa) in an
iCycler iQ system (Bio-Rad; Hercules, CA). The mRNA expression levels of
the interested genes were normalized to that of Gusb.
Cell proliferation assay
Cells were plated in 96-well plate. After various treatments as indicated, the
cells were subjected to proliferation assays using a BrdU Cell Proliferation
Assay Kit (#2750, Millipore) following the manufacturer’s protocol.
Immunoprecipitation, in vitro kinase assay, and immunoblot
analysis
Cell lysis was obtained with lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl,
10% glycerol, 1 mM EDTA, 50mM NaF, and 0.1% NP-40) supplemented
with protease and phosphatase inhibitors. For immunoprecipitation,
soluble products were incubated with antibodies as indicated at 4 °C
overnight, followed by incubation with Protein A/G Plus-Agarose (Santa
Cruz Biotechnology) at 4 °C for 2 h. Complexes were separated from the
beads and then boiled for 10min. For in vitro kinase assay, purified His-
tagged Gli2 fragment proteins were incubated with purified JNK1 proteins
(Millipore) in the presence of 50mM ATP in a kinase buffer [20mM
MgCl2,100mM ATP, 2 mM DTT, 50 mM inhibitors as indicated and 40mM
Tris-HCl(pH 7.5)] for 30 min at 30 °C. The kinase reaction was quenched by
the addition of 5× sample loading buffer and boiling at 100 °C for 10min.
Reaction products were subjected to sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE) and Coomassie Blue staining.
The proteins were separated by SDS-PAGE, electrophoretically trans-
ferred to polyvinylidene fluoride membranes, and subjected to routine
immunoblot analysis with interested antibodies as indicated. The antibody
against the phosphorylation of Gli2T1546 was produced using the
synthetic phosphorylated peptides CSSRLTT(p)PRN as antigen, and purified
on a phosphopeptide column (EZBiolab Inc, Carmel, IN).
Mass spectrometry and data analysis
Recombinant His-Gli2 fragments purified from E. coli was incubated in vitro
with or without recombinant JNK1 protein in the presence of 50mM ATP
at 30 °C for 30min. The samples were resolved by SDS-PAGE and stained
with Coomassie blue. The Gli2 fragment bands were cut and digested. The
resulting peptides were subjected to the enrichment of phosphorylated
peptides by using TiO2. The enriched phosphorylated peptides were
analyzed on the Q Exactive HF mass spectrometer (Thermo Scientific). The
identification and quantification of phosphorylated peptides was done by
MaxQuant. The tandem mass spectra were searched against UniProt
human protein database together with a set of commonly observed
contaminants. The precursor mass tolerance was set as 20 ppm, and the
fragment mass tolerance was set as 0.1 Da. The cysteine carbamidomethy-
lation was set as a static modification, and the methionine oxidation as
well as serine, threonine and tyrosine phosphorylations were set as
variable modifications. The FDR at peptide spectrum match level and
protein level were controlled below 1%.
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Hematoxylin and eosin staining was routinely performed. For immunohis-
tochemistry, tissue microarray slides were deparaffinised, rehydrated by an
alcohol series, and incubated with citrate buffer at 95 °C for 40min for
antigen retrieval and incubated overnight at 4 °C with the primary
antibodies as indicated. After three washes, tissue microarray slides were
incubated with biotinylated anti-mouse or anti-rabbit IgG and incubated
with avidin-biotin-peroxidise conjugates. For the quantitative analysis, a
Histo score (H-score) was calculated based on the staining intensity and
percentage of stained cells using the Aperio ScanScope systems. The
intensity score was defined as follows: 0, no appreciable staining in cells; 1,
weak staining in cells comparable with stromal cells; 2, intermediate
staining; 3, strong staining. The fraction of positive cells was scored as
0–100%. The H-score was calculated by multiplying the intensity score and
the fraction score, producing a total range of 0–300. Tissue sections were
examined and scored separately by two independent investigators blinded
to the clinicopathologic data.
Statistical analysis
Statistical differences were analyzed by the two-tailed Student’s t-test,
Spearman’s test, and Chi-square test. P value less than 0.05 was considered
as significant. Asterisks denote statistical significance (#P > 0.05; *P < 0.05;
**P < 0.01; and ***P < 0.001).
RESULTS
PGE2 non-canonically promotes the Hh activity in colorectal
cancer cells in a Smo-independent manner
Chronic inflammation has emerged as one of the key risk factors
for initiation, and progression of colorectal cancers. Using Gli-
dependent luciferase reporter activity as a Hh activity readout, we
observed that PGE2 profoundly increased the Gli activity in
multiple colorectal cancer cell lines, including LS174T, SW480,
SW620, and DLD-1 cells (Fig. 1A), in a time-dependent manner,
reaching maximum at about 6 h (Fig. 1B). However, PGE2
exhibited no effect on the luciferase activity of the mutant Gli-
dependent luciferase reporter plasmid (Fig. 1A). PGE2-stimulated
Gli activity could be obviously abolished by specific Gli
antagonists GANT61 [23], and JQ1 [24], but not by As2O3
[25, 26] (Fig. 1C), possibly due to the context-dependent
characteristics of Gli inhibitors [27]. These observations were
recapitulated by using Gli target genes Gli1 [28], Bcl-2 [29], and
twist1 [30] as readouts of Hh activity in LS174T cells (Fig. 1D).
Comparable to the elevated Gli activity, PGE2 increased the
proliferation of all of these tested colorectal cancers cells in a Gli-
dependent manner, as revealed by the inhibitory effect of either
Gli inhibitors GANT61 and JQ1 (Fig. 1E), or genetic silencing Gli2
by small interfering RNA (siRNA) (Fig. 1F, G). Notably, the
proliferation of colorectal cancers cells blocked by As2O3 might
be caused by its pro-apoptotic effect [31, 32] (Fig. 1E), rather by
influence on the Hh activity, due to its inability of inhibiting Hh
activity (Fig. 1C, D). Taken together, these results demonstrate that
PGE2 may non-canonically promote Hh activity and consequently
the proliferation of colorectal cancer cells.
In addition to PGE2, numerous inflammatory cytokines have
also been shown to be involved in initiation, and progression of
colorectal cancers, such as tumor necrosis factor α (TNF-α), and
interleukin 6 (IL-6) [33]. We then asked whether TNF-α, and IL-6
can also non-canonically promote Hh activity. Unexpectedly, we
observed that both TNF-α, and IL-6 exhibited no significant effect
Fig. 1 PGE2 non-canonically promotes the Hh pathway activity in colorectal cancer cells. A, B Luciferase assay for Gli transcriptional activity
in colorectal cancer cells with or without PGE2 (1 μM) stimulation. Cells were transfected with GliBS-Luciferase or mGliBS-Luciferase plasmids
plus TK-Renilla, and then treated with PGE2 for 6 h (A) or 1–12 h (B). GliBS is a Gli-responsive reporter, and mGliBS is a Gli-unresponsive
reporter. Error bars represent SD (n= 3). C Luciferase assay for Gli transcriptional activity in colorectal cancer cells subjected to PGE2 with or
without Gli inhibitors As2O3 (10 μM), GANT61 (20 μM), and JQ1 (1 μM) for 6 h. Error bars represent SD (n= 3). D The mRNA levels of Gli target
genes in colorectal cancer cells were examined by real-time PCR and normalized to the mRNA level of gusb. Cells were exposed to PGE2 (1 μM)
with or without As2O3 (10 μM), GANT61 (20 μM), and JQ1 (1 μM) for 6 h. Error bars represent SD (n= 3). E The proliferation of colorectal cancer
cells was examined with BrdU assays. Cells were exposed to PGE2 (1 μM) with or without As2O3 (10 μM), GANT61 (20 μM), and JQ1 (1 μM). Error
bars represent SD (n= 3). F Immunoblot analysis of Gli2 expression in LS174T cells transfected with Gli2 siRNA. G The proliferation of
colorectal cancer cells LS174T and SW480 was examined with BrdU assays. The cells were transfected with Gli2 siRNA followed by treatment
with or without PGE2 (1 μM). Error bars represent SD (n= 3).
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on the Gli-luciferase activity (Fig. S1A). Consistently, both TNF-α,
and IL-6 failed to increase the mRNA expression of Gli target genes
Gli1, Bcl-2, and twist1 (Fig. S1B). These data suggest that PGE2 may
be the predominant inflammatory factor involved the abnormal
and non-canonical activation of Hh activity during the initiation,
and progression of colorectal cancer.
Considering that Smo is a critical molecular target of the vast
majority of current Hh inhibitors [34, 35], we then set out to explore
whether Smo is involved in the PGE2-provoked Hh activity and
proliferation of colorectal cancer cells. We observed that in contrast
to Gli inhibitors JQ1, either Smo antagonists GDC-0449 (GDC) [36],
and NVP-LDE-225 (LDE) [37] (Fig. S2A, B), or genetic silencing Smo by
siRNA (Fig. S2D–F) was unable to block the Hh activity in response to
PGE2, as evidenced by no alterations of Gli-luciferase activity (Fig.
S2A and S2E) and mRNA expression of Hh target genes Gli1, Bcl-2,
and twist1 (Fig. S2B–F). Consistent with the unaffected Hh activity,
either Smo antagonists GDC, and LDE (Fig. S2C), or genetic silencing
Smo (Fig. S2G) also failed to inhibit the proliferation of colorectal
cancer cells stimulated by PGE2. These data suggest that Smo is
dispensable for PGE2-stimulated Gli activity and proliferation of
colorectal cancer cells. Meanwhile, we also observed that N-terminal
SHh conditioned medium (ShhN CM) failed to stimulate the Gli
activity and proliferation of colorectal cancer cells (Fig. S2A–C),
consistent with the observations in previous study [11].
PGE2 protects Gli2 from ubiquitin-proteasomal degradation
by activating JNK
Given that ubiquitin proteasomal degradation is one of the major
means for canonical Hh pathway to regulate Gli activity [3], we then
asked whether PGE2 also promotes the Gli activity via ubiquitin
proteasomal degradation. PGE2 treatment of colorectal cancer cells
increased the abundance of Gli1 (Fig. S3A) and Gli2 proteins (Fig. 2A),
reaching maximum at approximately 1 h, with no appreciable effect
on the expression of Gli3 protein (Fig. S3A). As Gli2 is regarded as the
primary activator for initiating the Hh pathway [3], we thus focused
our further investigations on Gli2. Despite the increase of Gli2
abundance at protein level by PGE2, the transcript level of Gli2 was
not altered by PGE2 treatment (Fig. 2B). Moreover, in the presence of
de novo protein synthesis inhibitor cycloheximide (CHX), PGE2
obviously reduced the turnover of Gli2 in LS174T cells (Fig. 2C and
Fig. S3B). These observations collectively indicate that PGE2 regulates
Gli2 protein expression by increasing its protein stability at post-
translational level. Considering that kinases have been the most
successful targets for developing mechanisms-based anticancer
drugs, we continued to determine whether kinases are involved in
PGE2-induced Gli2 protein expression at posttranslational level.
Among multiple small molecular inhibitors of kinases, including
SP600125 (SP), Rapamycin (Rap), PD98059 (PD), SB203580 (SB),
LY294002 (LY), and Ro31-8220 (Ro31), only JNK inhibitor SP was able
Fig. 2 PGE2 protects Gli2 from ubiquitin-proteasomal degradation by activating JNK. A Expression of Gli2 protein in LS174T and DLD-1
cells treated with PGE2 for different time intervals as indicated was analyzed by western blotting. B The mRNA level of Gli2 in LS174T and DLD-
1 cells treated with PGE2 for different time intervals was examined by real-time PCR and normalized to the mRNA level of gusb. Error bars
represent SD (n= 3). C Expression of Gli2 protein in LS174T cells treated with CHX (10 μg/ml), PGE2 (1 μM), and JIP (2 μM) as indicated for
different time intervals was analyzed by western blotting. D Immunoblot analysis of Gli2 protein expression in LS174T cells treated with PGE2
(1 μM) in combination with SP (10 μM), Rapa (100 nM), PD (10 μM), SB (10 μM), LY (10 μM), RO31 (1 μM) for 1 h, respectively. E Immunoblot
analysis of Gli2 protein expression in LS174T and DLD-1 cells treated with PGE2 with or without SP, TAT, and JIP as indicated for 1 h. F
Immunoblot analysis of Gli2 protein expression in LS174T and DLD-1 cells. Cells were transiently transfected with GFP or Jnk1a1(apf ), followed
by exposure to PGE2 with or without MG132 (10 μM), and chloroquine (10 μM) as indicated for 1 h. G Immunoprecipitation-western blot
analysis of the ubiquitination of Gli2 (detected with anti-HA) in LS174T cells expressing HA-tagged ubiquitin, and Myc-tagged Gli2 with
various combinations of treatment with PGE2, SP (10 μM), JIP (2 μM), TAT (2 μM), and MG132 (10 μM) as indicated 1 h. H Immunoprecipitation-
western blot analysis of the ubiquitination of Gli2 (detected with anti-Gli2) in LS174T cells expressing GFP, Jnk1a1(apf ), and HA-tagged
ubiquitin with various combinations of treatment with PGE2, and MG132 as indicated for 1 h. I Immunoprecipitation-western blot analysis of
the ubiquitination of Gli2 (detected with anti-Gli2) in LS174T cells expressing MKK7B2Jnk1a1, MKK7B2Jnk1a1 (APF), and HA-tagged ubiquitin
after exposure to MG132 as indicated for 1 h.
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to abrogate PGE2-elicited enhancement of Gli2 expression (Fig. 2D).
Meanwhile, we found that PGE2 treatment resulted in phosphoryla-
tion of JNK, reaching maximum at around 10–30min (Fig. S3C).
These observations indicate the involvement of JNK in the
posttranslational modification of Gli2. Such argument was further
supported by the observations of restoring PGE2-elicited decrease of
Gli2 turnover by peptide JNK inhibitor TAT-TI-JIP (JIP) (Fig. 2C and Fig.
S3B) and decreasing Gli2 expression by JIP and SP (Fig. 2E). TAT was
used as a negative control of peptide JNK inhibitor JIP. Meanwhile,
we found that a proteasomal inhibitor MG132, but not a lysosomal
inhibitor chloroquine, obviously rescued the down-regulation of Gli2
expression elicited by JNK dominant negative mutant Jnk1a1(apf)
[38] (Fig. 2F), suggesting that PGE2 increased the stability of Gli2 by
protecting Gli2 from proteasomal degradation via activating JNK.
Furthermore, PGE2 treatment obviously diminished the ubiquitina-
tion of Gli2, which could be restored by small molecular JNK
inhibitors SP and JIP (Fig. 2G) or Jnk1a1(apf) (Fig. 2H). Meanwhile, we
observed that JNK activation by transfection of MKK7B2Jnk1a1, a
constitutively active JNK mutant [38], significantly abolished the
ubiquitination of Gli2 (Fig. 2I). Taken together,these data demonstrate
that colorectal cancer cells may hijack PGE2 to enable the evasion of
Gli2 from ubiquitin proteasomal degradation by activating JNK.
JNK activation by PGE2 protects Gli2 from ubiquitin-
proteasomal degradation by phosphorylating Gli2 at Thr1546
Given that JNK is a Serine/Threonine (Ser/Thr) kinase, we then set
out to explore whether JNK enables the evasion of Gli2 from
ubiquitin proteasomal degradation by phosphorylating Gli2. We
first characterized the physical interaction between JNK and Gli2.
As shown in Fig. 3A, PGE2 promoted the binding of endogenous
JNK1 to endogenous Gli2, and this physical interaction was
dramatically diminished by JNK inhibitor SP (Fig. 3A). This
phenomenon was recapitulated with exogenous JNK1 and Gli2
(Fig. 3B). Meanwhile, by immunoblotting with an anti-phospho-
Ser/Thr antibody, we observed that PGE2 treatment caused Ser/
Thr phosphorylation of endogenous (Fig. 3C) and exogenous (Fig.
3D) Gli2, and JNK inhibitor JIP and SP obviously abolished the
PGE2-elicited Ser/Thr phosphorylation of Gli2 (Fig. 3C, D). These
results indicate that Gli2 represents a substrate of JNK.
Furthermore, in vitro kinase assay showed that a Gli2 fragment
containing the 1000–1587 amino acids, Gli2-F3, was phosphory-
lated by recombinant JNK1 (Fig. 3E), confirming that Gli2 is a bona
fide substrate of the kinase JNK. To further identify the JNK-
mediated phosphorylation sites on Gli2-F3, we harvested the Gli2-
F3 protein from in vitro kinase assay and performed mass
spectrometry analysis. The mass spectrometry analysis detected
the phosphorylation of Gli2-F3 on Thr1546 (Fig. S4A). Furthermore,
mutation of Thr1546 to alanine (Gli2-F3 T1546A) abolished the
phosphorylation in response to recombinant JNK1 (Fig. 3F),
confirming that Thr1546 is the phosphorylation site of Gli2
protein by JNK1.
To further explore whether Gli2 may be phosphorylated by
PGE2-JNK signaling axis at Thr1546, we developed a rabbit
polyclonal antibody that specifically recognizes phosphorylated
Fig. 3 JNK activation by PGE2 protects Gli2 from ubiquitin-proteasomal degradation by phosphorylating Gli2 at Thr1546. A
Immunoprecipitation-western blot analysis of the interaction between endogenous Gli2 with JNK in 293T cells treated with PGE2, SP, and
MG132 as indicated for 1 h. B Immunoprecipitation-western blot analysis of the interaction between exogenous Gli2 with JNK in 293T cells
expressing Flag-tagged JNK1, andMyc-tagged Gli2 after exposure to PGE2, SP, and MG132 as indicated for 1 h. C Immunoprecipitation-western
blot analysis of Thr/Ser phosphorylation of endogenous Gli2 in LS174T cells after exposure to PGE2, SP, and MG132 as indicated for 1 h. D
Immunoprecipitation-western blot analysis of Thr/Ser phosphorylation of exogenous Gli2 in LS174T cells expressing HA-tagged Gli2 after
exposure to PGE2, SP, and MG132 as indicated for 1 h. E The in vitro kinase assay was performed with recombinant JNK1 and indicated His-
tagged Gli2 fragments, followed by immunoblotting with anti-phosphorylation-Thr/Ser antibody. F The in vitro kinase assay was performed
with recombinant JNK1 and His-tagged Gli2-F3 fragments and His-tagged Gli2-F3 harboring the alanine substitution of theronine 1546 (Gli2-
F3 T1546A), followed by immunoblotting with anti-phosphorylation-Thr/Ser antibody. G Immunoblot analysis of Thr1546 phosphorylation of
Gli2 in LS174T cells expressing GFP, and Jnk1a1(apf ) after exposure to PGE2, MG132 as indicated for 1 h using specific phosphor-Gli2Thr1546
antibody. H Immunoblot analysis of Myc-tagged Gli2 (Gli2-Myc WT), Myc-tagged Gli2 with the glutamine substitution of threonine 1546 (Gli2-
Myc T1546E), and Myc-tagged Gli2 with the alanine substitution of threonine 1546 (Gli2-Myc T1546A) in LS174T cells treated with PGE2 as
indicated for 1 h. I Immunoprecipitation-western blot analysis of the ubiquitination of Gli2 (detected with anti-HA) in LS174T cells expressing
HA-tagged ubiquitin, Gli2-Myc WT, Gli2-Myc T1546E, and Gli2-Myc T1546A after exposure to PGE2, and MG132 as indicated for 1 h.
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Thr1546 of Gli2 (p-Gli2T1546). Using this antibody, we observed
that PGE2 treatment resulted in obvious Gli2 Thr1546 phosphor-
ylation, which was diminished by limiting Gli2 expression with
Gli2 siRNA (Fig. S4B), therefore, confirming the suitability of this
antibody. Ectopic expression of MKK7B2Jnk1a1 [38], but not its
negative control MKK7B2Jnk1a1(APF) [38], led to exogenous Gli2
Thr1546 phosphorylation (Fig. S4C). Furthermore, suppressing the
JNK function by Jnk1a1(apf) [38] (Fig. 3G) or JNK inhibitor SP and
JIP (Fig. S4D) significantly abolished the Gli2 Thr1546 phosphor-
ylation in response to PGE2 (Fig. 3G and Fig. S4D). These results
further strengthen that JNK after activated by PGE2 may
phosphorylate Gli2 at Thr1546.
To further elucidate the molecular basics behind how JNK
regulates the ubiquitination of Gli2, we then continued to
examine whether Gli2 Thr1546 phosphorylation is involved in
JNK-mediated evasion of Gli2 from proteasomal-ubiquitin degra-
dation in response to PGE2. We found that mutation of Thr1546 to
glutamine (Gli2T1546E), which is structurely similar with phos-
phorylation amino acid to mimick the phoshphorylated Gli2,
rendered exogenous Gli2 resistant to degradation in the absence
of PGE2 (Fig. 3H). Conversely, PGE2 lost the ability to protect
exogenous Gli2 from degradation when Thr1546 was mutated to
alanine (Gli2T1546A), which was designed to mimic the non-
phosphorylated Gli2 (Fig. 3H). Furthermore, as shown in Fig. 3I,
exogenous Gli2T1546E exhibited much less ubiquitination level in
the absence of PGE2 when compared to that of Gli2 wild type
(Gli2 WT). However, Gli2T1546A possessed much more ubiquitina-
tion level no matter whether PGE2 exposure or not (Fig. 3I). These
data demonstrate that the evasion of Gli2 from proteasomal-
ubiquitin degradation in response to PGE2 treatment requires JNK
activation, thereby further phosphorylating Gli2 at Thr1546.
JNK is required for the Hh activation and proliferation of
colorectal cancer cells elicited by PGE2
As we have determined that JNK is required for the evasion of Gli2
from proeasomal-ubiquitin degradation in response to PGE2 by
phosphorylating Gli2 at Thr1546, we then set out to test whether
JNK is involved in the Hh activation and the consequent
proliferation of colorectal cancer cells elicited by PGE2. We
observed that JNK inhibition by JIP and SP abrogated the
enhancement of both Gli luciferse reporter activity (Fig. 4A) and
transcripts of Gli target genes Gli1, Bcl-2, and twist1 (Fig. 4B) in
response to PGE2. The decrease of Hh activity elicited by SP and
JIP paralleled their inhibitory effect on proliferation of colorectal
cancer cells (Fig. 4C). Moreover, artificially forced expression of JNK
constitutively active mutant MKK7B2Jnk1a1 dramatically increased
the Hh activity, as reflected by Gli-luciferase activity (Fig. 4D) and
transcripts of Gli target genes Gli1, Blc-2, and twist1 (Fig. 4E), which
both were obviously diminished by specific molecular Gli
antagonists GANT61, and JQ1, but not by As2O3 (Fig. 4D, E).
Comparable results were obtained when we measured the
proliferation of colorectal cancer cells (Fig. 4F). Similar to above
data as shown in Fig. 1, As2O3 exhibited no inhibitory effect on the
Hh activity provoked by MKK7B2Jnk1a1, but suppressed the
MKK7B2Jnk1a1-stimulated proliferation of colorectal cancer cells
(Fig. 4D–F). These observations were further confirmed by ectopic
expression of JNK dominant negative mutant Jnk1a1(apf) (Fig.
4G–I). Hence, these data suggest that JNK activated by PGE2 is
essential for PGE2-elicited Hh activity and the consequent
proliferation of colorectal cancer cells.
We next continued to explore whether JNK-mediated Gli2
Thr1546 phosphorylation is essential for Hh activity and prolifera-
tion of colorectal cancer cells in response to PGE2. Contrary to
transfection with GFP, and Gli2 WT, transfection with Gli2T1546A
rendered PGE2 unable to promote the Gli-luciferase activity and
proliferation of LS174T cells (Fig. 4J, K). On the other hand,
transfection of Gli2T1546E obviously increased the Gli-luciferase
activity and proliferation of LS174T cells (Fig. 4L, M). Hence, these
results showed that JNK-mediated Gli2 Thr1546 phosphorylation is
required for the PGE2-dependent Hh activity and proliferation of
colorectal cancer cells.
PGE2-JNK signaling axis promotes intestinal tumor growth by
non-canonically stimulating Hh activity in a Smo-independent
manner in ApcMin/+ mice
We next set out to confirm whether PGE2-JNK signaling axis may
promote the Hh activity in vivo using the ApcMin/+ mice, which has
been frequently used as a model for human familial adenomatous
polyposis and a premalignant model for human colorectal cancer
[39, 40]. Treatment of ApcMin/+ mice with PGE2 accelerated
intestinal adenoma growth, which was obviously suppressed by
JNK and Gli inhibitor SP and JQ1, respectively, but not by Smo
inhibitor GDC (Fig. 5A, B). In accordance with the observations on
tumor burden, PGE2 treatment resulted in dramatic increase of Hh
activity as reflected by the Gli1, Bcl-2, and twist1 mRNA expression
of the intestinal adenoma cells isolated from the ApcMin/+ mice
(Fig. 5C). Furthermore, we observed that small molecular inhibitors
SP and JQ1, significantly abolished the enhancement of Hh
activity caused by PGE2 treatment, as evidenced by the down-
regulation of Gli1, Bcl-2, and twist1 mRNA expression (Fig. 5C).
Meanwhile, Smo inhibitor GDC exhibited no effect on the Hh
activity provoked by PGE2 (Fig. 5C). Collectively, these data
obtained from ApcMin/+ mice further confirmed that PGE2-JNK
signaling axis may non-canonically promote Hh activity in a Smo-
independent manner by protecting Gli2 from degradation (Fig.
5D), and consequently promote the development of colorectal
cancer growth.
Phosphorylated JNK and Gli2T1546 are correlated with Gli2
expression in colorectal cancer
To determine the pathological relevance of our findings, we
analyzed the relationship between the expression of Gli2 and the
phosphorylation of JNK. All the commercially available antibodies
used in this experiment were suitable for IHC as indicated by the
vendor. The suitability of p-Gli2 (T1546) for immunohistochemistry
(IHC) staining was verified using phospho-peptide and non-
phospho-peptide, as shown in Fig. S5. Examination of the tissue
array of human colorectal cancer and adjacent non-tumor tissues
with IHC staining revealed the increased expression of Gli2, p-JNK,
p-Gli2T1546, and ki-67 compared with those in adjacent non-
tumor tissues (Fig. 6A, B). Meanwhile, the expression of Gli2 was
associated with expression of p-Gli2T1546, p-JNK, and ki-67,
respectively (Fig. 6C, D). Furthermore, Kaplan–Meier survival
analysis showed that the survival time for colorectal cancer
patients with high expression of p-Gli2T1546 was significantly
shorter than those with low expression of p-Gli2T1546 (Fig. 6E).
Take together, those data suggest that there is close association
between the expression of these proteins and the colorectal
cancer development.
DISCUSSION
Ligand-independent aberrant activation of Hh pathway caused by
genetic alteration of its critical components has been well
documented to be critical for driving the initiation and progres-
sion of basal cellular carcinoma, as well as subsets of medellu-
blastoma [5]. However, the contribution of Hh pathway to the
majority of solid tumors, such as pancreas, prostate, and colorectal
cancers, which have been supposed to possess aberrant activation
of Hh in a manner of ligand-dependent autocrine or paracrine
activation, remains far from being fully elucidated [41]. As for
sporadic colorectal cancer, it has been initially shown that ligand-
dependent autocrine activation of Hh pathway in colon cancer
cells is required for the growth and metastasis of colorectal
cancers [8, 9]. Meanwhile, accumulating evidence suggests that
ligand-dependent paracrine activation of Hh pathway in tumor
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stromal cells provides a supportive microenvironment for the
initiation and progression of colorectal cancers [10–14]. However,
Gerling et al. recently reported that stromal Hh signaling was
found to be downregulated and promoted the development of
colorectal cancer, while its restoration might function as a colonic
tumor suppressor [16].
Given the complexity of the initiation and progression of
colorectal cancer, we explored the impact of Hh signaling to the
proliferation of colorectal cancer cells under the circumstance of
inflammatory factors intimately involved the initiation and
progression of colorectal cancer. We demonstrate that PGE2
non-canonically promotes Hh activation and consequently the
proliferation of colorectal cancer cells in a Smo-independent
manner. Meanwhile, we found that PGE2 might be the
predominant inflammatory factor involved in provoking the
non-canonical activation of Hh in colorectal cancer cells, as other
inflammatory factor intimately associated with colorectal cancer,
such as IL-6, and TNF-α, failed to enhance the Hh activity in
colorectal caner cells. Mechanistically, PGE2 activates the down-
stream effectors JNK, thereby protecting Gli2 from proteasomal-
ubiquitin degradation by phosphorylating Gli2 at Thr1546. Wang
et al. demonstrated that mTOR/S6K1 pathway non-canonically
stimulated Gli activity through S6K1-mediated Gli1 phosphoryla-
tion at Ser84, which releases Gli1 from its endogenous inhibitor,
SuFu protein, in esophageal adenocarcinoma cells [42]. However,
our lab found that colorectal cancer cells, such as LS174T and
SW480 cells exhibited little appreciable expression of Sufu protein
(data to be published), suggesting a dictinct mechanisms for
kinase JNK’s effect on Gli activity. Hence, our study provides an
novel insight into the mechanisms underlying how Hh signaling is
involved in the initiation and progression of colorectal cancer, and
a rationale for the future evaluation of chemopreventive and
Fig. 4 JNK is required for the Hh activation and proliferation of colorectal cancer cells elicited by PGE2. A Luciferase assay for Gli
transcriptional activity in colorectal cancer cells LS174T treated by PGE2, SP, TAT, JIP as indicated for 6 h. Error bars represent SD (n= 3). B The
mRNA levels of Gli target genes in LS174T cells treated by PGE2, SP, TAT, JIP as indicated for 6 h were examined by real-time PCR and
normalized to the mRNA level of gusb. Error bars represent SD (n= 3). C The proliferation of colorectal cancer cells LS174T treated by PGE2, SP,
TAT, JIP as indicated for 6 h was examined with BrdU assays. Error bars represent SD (n= 3). D Luciferase assay for Gli transcriptional activity in
colorectal cancer cells LS174T and SW480 cells expressing GFP, MKK7B2Jnk1a1, and MKK7B2Jnk1a1 (APF) after exposure to Gli inhibitors As2O3
(10 μM), GANT61 (20 μM), and JQ1 (1 μM) as indicated for 6 h. Error bars represent SD (n= 3). E The mRNA levels of Gli target genes in
LS174T cells expressing GFP, MKK7B2Jnk1a1, and MKK7B2Jnk1a1 (APF) were examined by real-time PCR and normalized to the mRNA level of
gusb after exposure to Gli inhibitors As2O3 (10 μM), GANT61 (20 μM), and JQ1 (1 μM) as indicated for 6 h. Error bars represent SD (n= 3). F The
proliferation of colorectal cancer cells LS174T and SW480 cells expressing GFP, MKK7B2Jnk1a1, and MKK7B2Jnk1a1 (APF) was examined with
BrdU assays after exposure to Gli inhibitors As2O3 (10 μM), GANT61 (20 μM), and JQ1 (1 μM) as indicated for 6 h. Error bars represent SD (n= 3).
G Luciferase assay for Gli transcriptional activity in colorectal cancer cells LS174T expressing GFP, and Jnk1a1 (APF) after treated by PGE2 for
6 h. Error bars represent SD (n= 3). H The mRNA levels of Gli target genes in colorectal cancer cells LS174T expressing GFP, and Jnk1a1 (APF)
after treated by PGE2 for 6 h were examined by real-time PCR and normalized to the mRNA level of gusb. Error bars represent SD (n= 3). I The
proliferation of colorectal cancer cells LS174T expressing GFP, and Jnk1a1 (APF) after treated by PGE2 for 6 h was examined with BrdU assays.
Error bars represent SD (n= 3). J Luciferase assay for Gli transcriptional activity in colorectal cancer cells LS174T cells expressing GFP, Gli2 WT,
and Gli2T1546A after exposure to PGE2 as indicated for 6 h. Error bars represent SD (n= 3). K The proliferation of colorectal cancer cells
LS174T cells expressing GFP, Gli2 WT, and Gli2T1546A after exposure to PGE2 was examined with BrdU assays. Error bars represent SD (n= 3).
L Luciferase assay for Gli transcriptional activity in colorectal cancer cellsLS174T cells expressing GFP, Gli2 WT, and Gli2T1546E. Error bars
represent SD (n= 3). M The proliferation of colorectal cancer cells LS174T cells expressing GFP, Gli2 WT, and Gli2T1546E was examined with
BrdU assays. Error bars represent SD (n= 3).
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selectively therapeutic strategies for colorectal cancers by target-
ing PGE2-JNK-Gli signaling route.
Our present study, together with reports from other labs,
indicates that Hh activity in colorectal cancer tissues is stimulated
by two distinct manners: (i) canonical and Smo-dependent
activation of Hh activity in colorectal cancer cells and stromal
cells [8–14], and (ii) non-canonical and Smo-independent activa-
tion provoked by PGE2 in colorectal cancer cells (Fig. 5D). This may
possibly explain the disappointing clinical trial results of Smo
inhibitors for treatment of colorectal cancer [15], as Smo inhibitors
can merely abolish the canonical and Smo-dependent Hh activity,
while leaving the PGE2-provoked and Smo-independent Hh
activity in colorectal cancer cells unaffected. In this context, it is
necessary to stratify the colorectal cancer patients by testing the
PGE2 level of patients in prior to treatment. Combination of COX2
inhibitors with Smo inhibitors will be much more precise for
colorectal cancer patients possessing aberrant PGE2 level and Hh
activity. As the final effector of Hh pathway, Gli has emerged as a
Fig. 5 PGE2-JNK signaling axis promotes intestinal tumor growth by non-canonically stimulating Hh activity in a Smo-independent
manner in ApcMin/+ mice. A, B The intestinal polyp number and size in ApcMin/+ mice treated with PGE2,GDC,SP, and JQ1 as indicated for
2 months. Error bars represent SD (n= 6). C The mRNA levels of Gli target genes in small intestine of mice treated with PGE2, GDC, SP, and JQ1
as indicated for 2 months. Error bars represent SD (n= 6). D Schematic model depicting the activation of Hh signaling pathway in cancer cells
and stromal cells in colorectal cancer.
Fig. 6 Phosphorylated JNK and Gli2T1546 are correlated with Gli2 expression in colorectal cancer. A H&E staining and IHC staining of the
primary human CRC tissue microarray. Scale bar, 50 μm. B Scatter plot showing the Gli2, p-Gli2T1546, p-JNK, and ki-67 staining level in
individual tumors as a ratio of staining in CRC versus paired non-cancer tissue. n= 86. C Correlation plot of p-Gli2T1546 and Gli2 IHC staining
(arbitrary units). Correlation was evaluated by nonparametric Spearman test. The coefficient of correlation (r), and the p value (p) are indicated.
n= 86. D Correlation plot of p-JNK and Gli2 IHC staining (arbitrary units). Correlation was evaluated by nonparametric Spearman test. The
coefficient of correlation (r), and the p value (p) are indicated. n= 86. E Correlation plot of ki-67 and Gli2 IHC staining (arbitrary units).
Correlation was evaluated by nonparametric Spearman test. The coefficient of correlation (r), and the p value (p) are indicated. n= 86. F
Kaplan–Meier survival analysis of CRC cases separated into two groups by the median value for phospho-Gli2T1546 staining. The p value was
calculated by log rank test.
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promising target for suppressing both canonical and non-
canonical Hh activity. Numerous direct and indirect Gli inhibitors
have been developed for treatment of Hh-driven cancers [43, 44].
However, it has been shown that Gli inhibitors function in a
context-dependent manner [27]. This argument is consistent with
our observations in this study. Our data reveals that Gli inhibitors
JQ1, an epigenetic modulator which indirectly inhibits transcrip-
tion of Gli by epigenetically targeting BRD4 [24], and GANT61 that
interferes with the binding of Gli to the transcription site of target
genes [23], suppresses the PGE2-provoked Hh activity and
exhibited comparable inhibitory effect on the proliferation of
colorectal cancer cells. However, As2O3, a Gli inhibitor that has
been shown to inhibit Hh activity by decreasing Gli expression
[25, 26], is unable to affect PGE2-provoked Hh activity, in despite
of obvious inhibitory effect on the proliferation of colorectal
cancer cells, possibly due to the its induction of apoptosis of
cancer cells [31, 32]. Hence, our observations suggest that much
more attention is needed, when choosing Gli inhibitors to
modulate the Hh activity in colorectal cancer cells.
Ubiquitination, the covalent attachment of ubiquitin to
substrate proteins, is a critical means to maintain the turnover
of great majority of proteins in mammalian cells [45]. The interplay
and crosstalk between phosphorylation and ubiquitination are a
recurrent theme in eukaryotic biology. Phosphorylation can
promote or inhibit ubiquitination, resulting in decreasing or
increasing proteasomal degradation, respectively. In the context
of inhibiting ubiquitination, it has been well recognized that
phosphorylation of a substrate by a kinase may protect this
substrate protein from ubiquitination and consequent degrada-
tion [46, 47]. Consistent with this paradigm, we found that Gli2
phosphorylation at Thr1546 caused by kinase JNK did endow Gli2
the ability of evading proteasomal-ubiquitin degradation. Hence,
our study replenishes the paradigm that phosphorylation of a
substrate by a kinase may protect this substrate protein from
ubiquitination and consequent degradation, therefore, contribut-
ing to our better interpretation of the mechanisms underlying
ubiquitination, which has emerged as a promising direction for
developing molecular targeted anti-cancer drugs. In summary, this
study demonstrate PGE2 non-canonically promotes Hh pathway
activity by suppressing the ubiquitination of Gli2 through JNK,
thereby promoting the progression of colorectal cancers. Hence,
This study not only presents evidence for understanding the
contribution of Hh to colorectal cancers, but also provides a novel
molecular portrait underlying how PGE2-activated JNK fine-tunes
the evasion of Gli2 from ubiquitin-proteasomal degradation.
Therefore, it proposes a rationale for the future evaluation of
chemopreventive and selective therapeutic strategies for color-
ectal cancers by targeting PGE2-JNK-Gli signaling route.
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